Profile data is unavailable for this security.
About the company
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to prevent and treat breast cancer. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
- Revenue in USD (TTM)0.00
- Net income in USD-29.69m
- Incorporated2009
- Employees10.00
- LocationAtossa Therapeutics Inc107 Spring StSEATTLE 98104-1005United StatesUSA
- Phone+1 (206) 588-0256
- Fax+1 (302) 636-5454
- Websitehttps://atossatherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CervoMed Inc | 8.08m | -4.15m | 156.33m | 8.00 | 37.05 | 21.90 | -- | 19.34 | 0.5113 | 0.5113 | 1.74 | 0.8648 | 0.6124 | -- | -- | 1,010,531.00 | -31.45 | -53.67 | -38.42 | -58.89 | -- | -- | -51.36 | -949.54 | -- | -- | 0.00 | -- | -- | -- | 86.07 | -- | -- | -- |
OptiNose Inc | 74.02m | -30.75m | 156.43m | 132.00 | -- | -- | -- | 2.11 | -0.2733 | -0.2733 | 0.659 | -0.8777 | 0.7453 | 0.8764 | 4.74 | 560,772.80 | -30.91 | -48.25 | -- | -98.95 | 88.98 | 86.96 | -41.47 | -131.66 | 2.17 | -1.16 | 4.16 | -- | -6.93 | 58.64 | 52.58 | -- | -27.96 | -- |
CytoDyn Inc | 0.00 | -51.69m | 156.71m | 12.00 | -- | -- | -- | -- | -0.055 | -0.055 | 0.00 | -0.1206 | 0.00 | -- | -- | 0.00 | -414.98 | -259.98 | -- | -- | -- | -- | -- | -235,303.80 | -- | -0.88 | -- | -- | -100.00 | -- | 62.14 | -- | -- | -- |
ProQR Therapeutics NV | 14.62m | -29.10m | 158.64m | 157.00 | -- | 4.35 | -- | 10.85 | -0.3584 | -0.3584 | 0.1801 | 0.4481 | 0.0957 | -- | -- | 93,136.34 | -18.83 | -35.51 | -23.01 | -40.51 | -- | -- | -196.75 | -926.31 | -- | -- | 0.3557 | -- | 118.51 | 10.58 | 56.35 | -- | 34.45 | -- |
P3 Health Partners Inc | 1.35bn | -67.27m | 158.69m | 400.00 | -- | 0.4089 | -- | 0.1173 | -0.5855 | -0.5855 | 11.86 | 1.23 | 1.57 | -- | 11.40 | 3,381,965.00 | -21.31 | -- | -90.11 | -- | 1.59 | 0.1781 | -13.57 | -56.93 | -- | -10.05 | 0.2368 | -- | 20.67 | 70.58 | 78.61 | -- | -11.20 | -- |
Alimera Sciences Inc | 90.22m | -22.66m | 159.79m | 159.00 | -- | 3.93 | -- | 1.77 | -1.57 | -1.57 | 2.42 | 0.7762 | 0.8989 | 7.11 | 3.43 | 567,415.10 | -21.34 | -19.08 | -25.84 | -27.37 | 86.52 | 86.80 | -23.74 | -19.55 | 2.51 | -0.0756 | 0.6323 | -- | 49.19 | 11.62 | -18.14 | -- | 236.53 | -- |
Rezolute Inc | 0.00 | -58.21m | 161.74m | 51.00 | -- | 2.28 | -- | -- | -1.14 | -1.14 | 0.00 | 1.77 | 0.00 | -- | -- | 0.00 | -52.46 | -58.48 | -55.28 | -63.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -26.13 | -- | 92.29 | -- |
Atossa Therapeutics Inc | 0.00 | -29.69m | 163.48m | 10.00 | -- | 1.90 | -- | -- | -0.2359 | -0.2359 | 0.00 | 0.6833 | 0.00 | -- | -- | 0.00 | -28.65 | -29.97 | -29.84 | -32.55 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.62 | -- | -33.90 | -- |
Adverum Biotechnologies Inc | 0.00 | -112.90m | 164.39m | 121.00 | -- | 0.9018 | -- | -- | -10.23 | -10.23 | 0.00 | 8.78 | 0.00 | -- | -- | 0.00 | -41.55 | -36.39 | -47.50 | -39.04 | -- | -- | -- | -5,279.60 | -- | -- | 0.00 | -- | -- | 17.43 | 24.18 | -- | -0.0247 | -- |
Outlook Therapeutics Inc | 0.00 | -159.13m | 165.48m | 24.00 | -- | -- | -- | -- | -11.48 | -11.48 | 0.00 | -6.10 | 0.00 | -- | -- | 0.00 | -281.52 | -214.69 | -2,060.72 | -1,843.48 | -- | -- | -- | -3,043.92 | -- | -26.75 | -- | -- | -- | -- | 10.70 | -- | -- | -- |
Kodiak Sciences Inc | 0.00 | -232.75m | 167.06m | 107.00 | -- | 0.6925 | -- | -- | -4.44 | -4.44 | 0.00 | 4.59 | 0.00 | -- | -- | 0.00 | -43.30 | -31.73 | -47.44 | -33.61 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.97 | -- | 134.76 | -- |
Galectin Therapeutics Inc | 0.00 | -44.78m | 169.04m | 14.00 | -- | -- | -- | -- | -0.7373 | -0.7373 | 0.00 | -1.14 | 0.00 | -- | -- | 0.00 | -177.94 | -92.08 | -373.85 | -121.97 | -- | -- | -- | -- | -- | -10.24 | 7.25 | -- | -- | -- | -15.26 | -- | -- | -- |
X4 Pharmaceuticals Inc | 0.00 | -128.91m | 169.62m | 93.00 | -- | 163.72 | -- | -- | -0.6968 | -0.6968 | 0.00 | 0.0062 | 0.00 | -- | -- | 0.00 | -108.98 | -61.53 | -133.20 | -69.20 | -- | -- | -- | -13,288.93 | -- | -- | 0.9815 | -- | -- | -- | -4.93 | -- | 12.03 | -- |
Sagimet Biosciences Inc | 2.00m | -27.92m | 170.10m | 10.00 | -- | 0.8952 | -- | 85.05 | -1.23 | -1.23 | 0.0862 | 5.95 | 0.018 | -- | -- | 200,000.00 | -25.18 | -- | -26.34 | -- | -- | -- | -1,395.90 | -- | -- | -- | 0.00 | -- | -- | -- | 8.60 | -- | -- | -- |
Rigel Pharmaceuticals Inc | 120.35m | -19.80m | 171.51m | 147.00 | -- | -- | -- | 1.43 | -0.1135 | -0.1135 | 0.69 | -0.1806 | 0.9623 | 0.9241 | 4.23 | 818,680.30 | -15.83 | -28.82 | -30.14 | -47.26 | 93.22 | 97.88 | -16.45 | -35.76 | 1.17 | -2.91 | 2.13 | -- | -2.79 | 21.30 | 57.16 | -- | 68.45 | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 31 Mar 2024 | 5.71m | 4.56% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 2.30m | 1.84% |
Laurion Capital Management LPas of 31 Mar 2024 | 2.23m | 1.78% |
Renaissance Technologies LLCas of 31 Mar 2024 | 1.39m | 1.11% |
Geode Capital Management LLCas of 31 Mar 2024 | 1.21m | 0.97% |
Millennium Management LLCas of 31 Mar 2024 | 1.01m | 0.81% |
Morgan Stanley & Co. LLCas of 31 Mar 2024 | 739.81k | 0.59% |
Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 628.55k | 0.50% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 493.57k | 0.39% |
HRT Financial LLCas of 31 Mar 2024 | 291.42k | 0.23% |